EUVIMEDEUVIMED entdecken
Open Access

ADAMTS13 or Caplacizumab Reduces the Accumulation of Neutrophil Extracellular Traps and Thrombus in Whole Blood of COVID-19 Patients under Flow

Noritaka Yada, Quan Zhang, Antonia Bignotti, Zhan Ye, X Long Zheng iD

Thrombosis and Haemostasis · 01.08.2024 · 124 (08) · 725-738

DOI: 10.1055/a-2253-9359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.08.2024. Verfasst von Noritaka Yada und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kanas City, Kansas, United States. Hauptthemen laut MEDLINE: Extracellular Traps, COVID-19, ADAMTS13 Protein, Thrombosis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, U.S. Department of Health and Human Services, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neutrophil NETosis and neutrophil extracellular traps (NETs) play a critical role in pathogenesis of coronavirus disease 2019 (COVID-19)-associated thrombosis. However, the extents and reserve of NETosis, and potential of thrombus formation under shear in whole blood of patients with COVID-19 are not fully elucidated. Neither has the role of recombinant ADAMTS13 or caplacizumab on the accumulation of NETs and thrombus in COVID-19 patients' whole blood under shear been investigated.

Methods

Flow cytometry and microfluidic assay, as well as immunoassays, were employed for the study.

Results

We demonstrated that the percentage of H3Cit + MPO+ neutrophils, indicative of NETosis, was dramatically increased in patients with severe but not critical COVID-19 compared with that in asymptomatic or mild disease controls. Upon stimulation with poly [I:C], a double strain DNA mimicking viral infection, or bacterial shigatoxin-2, the percentage of H3Cit + MPO+ neutrophils was not significantly increased in the whole blood of severe and critical COVID-19 patients compared with that of asymptomatic controls, suggesting the reduction in NETosis reserve in these patients. Microfluidic assay demonstrated that the accumulation of NETs and thrombus was significantly enhanced in the whole blood of severe/critical COVID-19 patients compared with that of asymptomatic controls. Like DNase I, recombinant ADAMTS13 or caplacizumab dramatically reduced the NETs accumulation and thrombus formation under arterial shear.

Conclusion

Significantly increased neutrophil NETosis, reduced NETosis reserve, and enhanced thrombus formation under arterial shear may play a crucial role in the pathogenesis of COVID-19-associated coagulopathy. Recombinant ADAMTS13 or caplacizumab may be explored for the treatment of COVID-19-associated thrombosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular TrapsCOVID-19ADAMTS13 ProteinThrombosisNeutrophilsSARS-CoV-2HumansMaleFemaleMiddle AgedAgedAdultCOVID-19 Drug TreatmentSingle-Domain Antibodies

Substanzen

ADAMTS13 ProteinADAMTS13 protein, humancaplacizumabSingle-Domain Antibodies

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kanas City, Kansas, United States.
  • Institute of Reproductive Medicine and Developmental Sciences, The University of Kansas Medical Center, Kanas City, Kansas, United States.

ORCID-Profile: X Long Zheng

Förderung

  • NHLBI NIH HHS
  • U.S. Department of Health and Human Services
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Yada, N., Zhang, Q., Bignotti, A., Ye, Z., & Zheng, X. L. (2024). ADAMTS13 or Caplacizumab Reduces the Accumulation of Neutrophil Extracellular Traps and Thrombus in Whole Blood of COVID-19 Patients under Flow. Thrombosis and Haemostasis, 124(08), 725-738. https://doi.org/10.1055/a-2253-9359

Vancouver

Yada N, Zhang Q, Bignotti A, Ye Z, Zheng XL. ADAMTS13 or Caplacizumab Reduces the Accumulation of Neutrophil Extracellular Traps and Thrombus in Whole Blood of COVID-19 Patients under Flow. Thrombosis and Haemostasis. 2024;124(08):725-738. doi:10.1055/a-2253-9359

BibTeX
@article{Yada2024,
  author = {Yada, Noritaka and Zhang, Quan and Bignotti, Antonia and Ye, Zhan and Zheng, X Long},
  title = {ADAMTS13 or Caplacizumab Reduces the Accumulation of Neutrophil Extracellular Traps and Thrombus in Whole Blood of COVID-19 Patients under Flow},
  journal = {Thrombosis and Haemostasis},
  year = {2024},
  volume = {124},
  number = {08},
  pages = {725--738},
  doi = {10.1055/a-2253-9359}
}
Kostenlos starten →